…
Ocumetics Technology Corp. engages in research, development, production, and sale of vision enhancement products in Canada. The company develops expandable intraocular lenses to eliminate the need for corrective lenses primarily for people over 45 years of age. The company was formerly known as Quantum Blockchain Technologies Ltd. and changed changed its name to Ocumetics Technology Corp. in August 2021. Ocumetics Technology Corp. was founded in 2012 and is headquartered in Calgary, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Ocumetics Technology Corp appears to develop intraocular lens technology aimed at improving vision outcomes for patients undergoing cataract or refractive lens procedures. Long-term growth may be supported by aging demographics and rising procedural volumes, and the company's novel lens approach could make it appealing to investors seeking exposure to ophthalmic device innovation.
The primary risks include early-stage development with limited clinical evidence, regulatory approval uncertainty, sparse public disclosure and low trading liquidity that may impede fundraising and commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 |
| Income before tax | -3.06M | -3.64M | -2.22M | -2.22M | -0.60M |
| Net income | -3.02M | -3.64M | -2.22M | -2.22M | -0.60M |
| Selling general administrative | 1.26M | 2.54M | 1.45M | 1.45M | 0.51M |
| Reconciled depreciation | 0.13M | 0.12M | 0.10M | 0.10M | 0.08M |
| Ebit | - | - | - | - | -0.65M |
| Ebitda | - | - | -2.09M | -2.09M | -0.51M |
| Operating income | -2.43M | -3.61M | -2.18M | -2.10M | -0.60M |
| Interest expense | 0.64M | 0.03M | 0.03M | 0.03M | 0.00M |
| Tax provision | -0.04M | - | - | - | - |
| Interest income | 0.04M | - | - | - | - |
| Net interest income | -0.60M | -0.03M | -0.03M | -0.03M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 2.43M | 3.61M | 2.18M | 2.10M | 0.60M |
| Total other income expense net | -0.04M | -0.01M | -0.01M | -0.09M | -0.05M |
| Net income from continuing ops | -3.02M | -3.64M | -2.22M | -2.22M | -0.60M |
| Net income applicable to common shares | - | - | - | - | -0.65M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 |
| Total assets | 2.32M | 1.04M | 1.37M | 1.37M | 0.83M |
| Intangible assets | 0.62M | 0.66M | 0.70M | 0.70M | 0.62M |
| Total liab | 4.26M | 0.95M | 0.54M | 0.54M | 1.10M |
| Total stockholder equity | -1.94M | 0.09M | 0.84M | 0.84M | -0.27M |
| Other current liab | - | - | - | - | 0.37M |
| Common stock | - | - | - | - | 1.51M |
| Capital stock | 7.80M | 7.45M | 5.36M | 5.36M | 1.51M |
| Retained earnings | -12.20M | -9.18M | -5.53M | -5.53M | -1.83M |
| Other liab | - | - | - | - | 0.50M |
| Other assets | - | - | - | - | 0.09M |
| Cash | 0.20M | 0.24M | 0.60M | 0.60M | 0.08M |
| Total current liabilities | 0.31M | 0.62M | 0.24M | 0.24M | 0.64M |
| Net debt | 3.76M | 0.09M | - | - | - |
| Other stockholder equity | - | - | - | - | 0.27M |
| Total current assets | 1.65M | 0.31M | 0.67M | 0.67M | 0.11M |
| Net tangible assets | - | - | - | - | -0.94M |
| Short term investments | 1.38M | - | - | - | - |
| Net receivables | - | 0.00M | 0.00M | 0.00M | 0.03M |
| Long term debt | 3.95M | 0.32M | 0.29M | - | - |
| Accounts payable | 0.23M | 0.55M | 0.17M | 0.17M | 0.06M |
| Non currrent assets other | - | - | - | - | 0.09M |
| Non current assets total | 0.68M | 0.73M | 0.70M | 0.70M | 0.71M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 |
| Investments | -1.38M | -0.14M | -0.07M | -0.07M | -0.21M |
| Change to liabilities | - | - | - | - | 0.24M |
| Total cashflows from investing activities | - | - | - | - | -0.21M |
| Net borrowings | 3.60M | - | - | - | - |
| Total cash from financing activities | 3.85M | 1.82M | 0.44M | 0.44M | 0.39M |
| Change to operating activities | - | - | - | - | 0.26M |
| Net income | -3.02M | -3.64M | -2.22M | -2.22M | -0.60M |
| Change in cash | -0.04M | -0.37M | -1.24M | -1.24M | 0.08M |
| Begin period cash flow | 0.24M | 0.60M | 1.84M | 1.84M | 0.00M |
| End period cash flow | 0.20M | 0.24M | 0.60M | 0.60M | 0.08M |
| Total cash from operating activities | -2.43M | -2.05M | -1.62M | -1.62M | -0.09M |
| Issuance of capital stock | 0.26M | 1.79M | 0.04M | 0.04M | 0.39M |
| Depreciation | 0.13M | 0.12M | 0.10M | 0.10M | 0.08M |
| Other cashflows from investing activities | - | - | - | - | -0.09M |
| Change to account receivables | 0.00M | 0.00M | -0.00M | -0.00M | -0.03M |
| Other cashflows from financing activities | - | - | - | - | -0.09M |
| Change to netincome | - | - | - | - | 2.01M |
| Capital expenditures | 0.08M | 0.14M | 0.07M | 0.07M | 0.12M |
| Change in working capital | -0.32M | 0.38M | -0.01M | -0.01M | 0.43M |
| Stock based compensation | 0.17M | 0.49M | 0.49M | 0.49M | 0.00M |
| Other non cash items | 0.64M | 0.61M | 0.03M | 0.03M | - |
| Free cash flow | -2.51M | -2.19M | -1.69M | -1.69M | -0.21M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| OTC Ocumetics Technology Corp |
- -% |
0.40 | - | - | - | 41.07 | -79.74 |
| ZEN ZEN Graphene Solutions Ltd |
0.01 1.89% |
0.54 | - | - | 79.84 | 5.93 | -14.24 |
| COV Covalon Technologies Ltd. |
0.03 0.70% |
4.29 | 65.00 | 23.81 | 1.71 | 2.04 | 26.39 |
Ocumetics Technology Corp. engages in research, development, production, and sale of vision enhancement products in Canada. The company develops expandable intraocular lenses to eliminate the need for corrective lenses primarily for people over 45 years of age. The company was formerly known as Quantum Blockchain Technologies Ltd. and changed changed its name to Ocumetics Technology Corp. in August 2021. Ocumetics Technology Corp. was founded in 2012 and is headquartered in Calgary, Canada.
| Name | Title | Year Born |
|---|---|---|
| Dr. Garth T. Webb | Founder, Chairman & Chief Scientific Officer | NA |
| Dr. Mark Lee | Pres & CEO | NA |
| Mr. Roger M. Jewett C.A., CPA | CFO & Director | NA |
| Dr. Doyle Stulting | Chief Medical Officer | NA |
| Mr. Dean E. Burns | President, CEO & Director | NA |
| Mr. Roger M. Jewett C.A., CPA | CFO & Director | 1964 |
| Dr. R. Doyle Stulting | Chief Medical Officer & Director | NA |
| Mr. Roger M. Jewett C.A., CPA | CFO & Director | 1965 |
| Dr. R. Doyle Stulting | Chief Medical Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.